Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sabatolimab in AML With MRD After Allogeneic Stem Cell Transplantation
2020-000869-17Phase 2Terminated
- Sponsor
- Novartis
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of sabatolimab in acute myeloid leukemia (AML) (2 arms), sponsored by Novartis. Primary endpoints: Incidence of dose limiting toxicities and Proportion without hematologic relapse after 6 cycles. Started Dec 2020; status: terminated.
02
Drugs
sabatolimab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2020-000869-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000869-17.